Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only
暂无分享,去创建一个
G. Patijn | R. V. van Dam | C. V. van Eijck | M. Polée | M. Besselink | V. D. de Meijer | M. Stommel | H. V. van Santvoort | S. Festen | D. Latifi | K. V. van Lienden | B. Koerkamp | M. Liem | L. Daamen | Y. Nio | H. Wilmink | G. Patijn | R. Bruijnen | Q. Molenaar | M. Walma | M. Besselink | L. Brada | C. V. van Eijck | L. Magermans | I. D. de Hingh | Olivier R. Busch | Koop Bosscha | Frank J. Wessels | Lisa G. Magermans | Yung C. Nio | Jan J. J. de Vries | K. Bosscha | Q. Molenaar | F. Wessels
[1] F. Daams,et al. Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort. , 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[2] P. Bossuyt,et al. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. , 2020, JAMA oncology.
[3] W. Harmsen,et al. Patient-Reported Quality of Life Before and After Chemoradiation for Intact Pancreas Cancer: a Prospective Registry Study. , 2020, Practical radiation oncology.
[4] R. Salem,et al. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer , 2020, Pancreas.
[5] R. Croner,et al. Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward , 2020, Cancers.
[6] B. Erickson,et al. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. , 2020, Annals of surgery.
[7] C. V. van Eijck,et al. Establishing and Coordinating a Nationwide Multidisciplinary Study Group: Lessons Learned by the Dutch Pancreatic Cancer Group. , 2020, Annals of surgery.
[8] C. V. van Eijck,et al. Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. , 2019, European journal of cancer.
[9] P. Malfertheiner,et al. Maintenance Therapy with FOLFIRI after FOLFIRINOX for Advanced Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis , 2019, Journal of oncology.
[10] O. Strobel,et al. Conversion Surgery for Advanced Pancreatic Cancer , 2019, Journal of clinical medicine.
[11] N. Takahashi,et al. Survival benefit of neoadjuvant therapy in patients with non‐metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention‐to‐treat analysis , 2019, Journal of surgical oncology.
[12] M. Sekimoto,et al. Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma , 2019, Annals of gastroenterological surgery.
[13] M. Tuveri,et al. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. , 2019, JAMA surgery.
[14] J. Cameron,et al. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. , 2019, Annals of surgery.
[15] N. Orsini,et al. Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer , 2019, Annals of surgery.
[16] G. Honda,et al. Decreased serum carbohydrate antigen 19–9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients , 2019, BMC Cancer.
[17] T. Hackert. Surgery for Pancreatic Cancer after neoadjuvant treatment , 2018, Annals of gastroenterological surgery.
[18] M. Besselink,et al. Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy. , 2018, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[19] J. Lacy,et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. , 2018, Journal of the National Cancer Institute.
[20] Hai Hu,et al. Predictors of Resectability and Survival in Patients with Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment with FOLFIRINOX. , 2017, Annals of surgery.
[21] M. Reni,et al. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] E. Nakakura,et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, The Journal of the National Comprehensive Cancer Network.
[23] M. Baltatzis,et al. Superior mesenteric artery (SMA) resection during pancreatectomy for malignant disease of the pancreas: a systematic review. , 2017, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[24] J. Laukkarinen,et al. Quality of life in patients with pancreatic ductal adenocarcinoma undergoing pancreaticoduodenectomy. , 2017, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[25] M. Büchler,et al. Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer , 2016, The British journal of surgery.
[26] T. Conroy,et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. , 2016, The Lancet. Oncology.
[27] D. Jäger,et al. Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients , 2016, Annals of surgery.
[28] A. Zwinderman,et al. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial , 2016, Trials.
[29] I. B. Borel Rinkes,et al. Health‐related quality of life after pancreatic resection for malignancy , 2016, The British journal of surgery.
[30] M. Gonen,et al. Health-Related Quality of Life After Pancreatectomy: Results From a Randomized Controlled Trial , 2016, Annals of Surgical Oncology.
[31] Jeffrey E. Lee,et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators , 2012, Cancer.
[32] D. Jäger,et al. Resection after neoadjuvant therapy for locally advanced, "unresectable" pancreatic cancer. , 2012, Surgery.
[33] K. McMasters,et al. Impact of post-operative complications on quality of life after pancreatectomy. , 2012, JOP : Journal of the pancreas.
[34] Alessandra Mattei,et al. Estimating and using propensity score in presence of missing background data: an application to assess the impact of childbearing on wellbeing , 2009, Stat. Methods Appl..
[35] I. B. Borel Rinkes,et al. Long-term health-related quality of life after pancreatic resection for malignancy in patients with and without severe postoperative complications. , 2018, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[36] Jeffrey W. Clark,et al. "Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer." , 2017, Annals of surgery.
[37] J. S. Karlsson,et al. Pathology reporting of pancreatic cancer following neoadjuvant therapy: challenges and uncertainties. , 2015, Cancer treatment reviews.
[38] F. Carbonnel,et al. FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort , 2014, Annals of Surgical Oncology.
[39] T. Conroy,et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[41] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.